Moretta
Allessandro Moretta, Genes IT
Patent application number | Description | Published |
---|---|---|
20080274468 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 11-06-2008 |
Allessandro Moretta, Genova IT
Patent application number | Description | Published |
---|---|---|
20110151472 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 06-23-2011 |
20110229486 | Monoclonal Antibodies Against NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 09-22-2011 |
20120329063 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 12-27-2012 |
Anthony Moretta, Elton GB
Patent application number | Description | Published |
---|---|---|
20150175340 | AEROSOL SPRAY PRODUCTION - A method and product for producing a soft sounding aerosol spray from a particulate suspension, said method and product involving a spray channel having an exit orifice of internal diameter of from 0.5 to 0.8 mm and a terminal section leading to the exit orifice of internal diameter from 0.5 to 0.8 mm for a length of 5 mm or greater, the terminal section of the spray channel including the exit orifice having a tubular internal surface free from obstacle. | 06-25-2015 |
Lorenzo Moretta, Genova IT
Patent application number | Description | Published |
---|---|---|
20080219980 | Bi-Specific Complexes for Targeting Cells Involved in Allergic-Type Reactions, Compositions and Uses Thereof - Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described. | 09-11-2008 |
20100285531 | Therapeutic and Diagnostic Methods and Compositions Targeting 4Ig-B7-H3 and its Counterpart NK Cell Receptor - The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein. | 11-11-2010 |
20130315892 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS TARGETING 4IG-B7-H3 AND ITS COUNTERPART NK CELL RECEPTOR - The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein. | 11-28-2013 |